Download now

White Paper

The Role of Local Laboratories in HIV and HCV Diagnosis and Prevention

With successful innovations in HIV and HCV treatment, increased viral load testing is key to preventing new infections. Community laboratories throughout the country are ready.

Download now

Despite strides to achieve national infection reduction initiatives, there’s more work to be done, and labs have a role to play.

When the SARS-CoV-2 emergency overwhelmed centralized laboratories in the U.S. with sudden, high demand for quick test results, hospital and community laboratories responded by developing or expanding their in-house testing capabilities. New investments in automated systems running fast, accurate nucleic acid amplification tests (NAATs) have equipped local laboratories with the technology needed to provide rapid, reliable viral load testing.

Now that the emergency has passed, these laboratories are ideally situated to expand their in-house testing to support national initiatives in other epidemics: HIV and HCV.

Karen Harrington, PhD, HCLD (ABB), Director of Scientific Affairs at Hologic, Inc. discusses the local laboratory’s role in HIV and HCV diagnosis and prevention.

Please complete the following form to download the free white paper:

*Required fields

Sections at a Glance

This white paper discusses how community laboratories bringing viral load testing in-house yield significant benefits for patients, clinicians, and laboratory professionals by:
  • Providing rapid results to clinicians who prescribe HIV drug therapies
  • Helping achieve the goal to eradicate HCV with their critical proximity to care
  • Growing talent and insights needed for strong collaborative work with in-network virologists and clinicians

About the Author

Karen Harrington, PhD, HCLD (ABB)

is Director of Scientific Affairs at Hologic, Inc. Dr. Harrington has more than 20 years of experience in molecular diagnostics having worked in research and development and clinical and regulatory affairs, successfully taking several molecular IVD products through clinical trials, FDA approval and commercialization. Harrington received her BS in Biology from Marquette University and her PhD in Molecular Genetics from Georgia State University. Dr. Harrington is also certified as a High-complexity Clinical Laboratory Director by the American Board of Bioanalysis and has directed CLIA/CAP accredited clinical laboratories performing molecular-based infectious disease and oncology testing.